Investigational new drugThyroid Analog
Compound 61408
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061408
Risk Class
MODERATE
Last Audit
Jan 25, 2108
Research Abstract
Thyroid Analog candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61408 is a thyroid analog asset inside thyroid analog innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in investigational new drug with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061408 with updates logged 2108-01-25.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61408Thyroid Analog Program 61408
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061408
- [2] Operations Pulse • Thyroid Analog innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61408